Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing pregabalin and BBCET. Pregabalin is a small molecule anticonvulsant and analgesic, primarily used for neuropathic pain, fibromyalgia, and as adjunctive therapy for partial-onset seizures. It acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release and neuronal excitability[1][6]. The identity of "BBCET" could not be confirmed from available sources; it does not correspond to any widely recognized pharmaceutical ingredient or code name in current medical literature or regulatory databases as of June 2025. Therefore, the mechanism of action, indications, developer information, and other details specific to "BBCET" are unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + BBCET.